<DOC>
	<DOCNO>NCT01397864</DOCNO>
	<brief_summary>This non-interventional treatment Registry Hereditary Angioedema ( HAE ) patient treat C1 inhibitor , either plasma-derived ( pdC1INH ) recombinant human form ( Ruconest ) , observe adverse event insufficient efficacy , assess immunological profile follow single repeat treatment Ruconest .</brief_summary>
	<brief_title>C1 Inhibitor Registry Treatment Hereditary Angioedema ( HAE ) Attacks</brief_title>
	<detailed_description>see</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>Decision treat HAE patient C1 inhibitor ( either Ruconest pdC1INH ) Patients must give write informed consent A diagnosis acquire C1INH deficiency ( AAE )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>HAE</keyword>
	<keyword>Angioedema</keyword>
	<keyword>Recombinant C1 Inhibitor</keyword>
	<keyword>rhC1INH</keyword>
	<keyword>registry</keyword>
</DOC>